We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Detects Breast Cancer Spread Earlier

By LabMedica International staff writers
Posted on 12 May 2016
More sensitive, non-invasive tests are required for secondary breast cancer, which occurs when new tumors grow in the bone, liver, lung or brain, to make diagnosis easier and for treatment to begin as early as possible.

Secondary breast cancer is difficult to diagnose before symptoms are experienced and occurs in up to a third of breast cancer patients, sometimes many years after seemingly successful treatment for localized, primary cancer that remained in the breast.

Scientists at the University of Westminster (London, UK) collected serum samples from breast cancer patients were recruited onto the study nine to15 months post breast cancer diagnosis, whereupon the first of five annual venipunctures was performed. More...
There were 207 patients who developed distant metastases by October 2012, of which 120 had available serum samples from year one and at least one other year of the study. In a nested case–control study of serum samples from breast cancer patients, of which 52 had developed a distant metastatic recurrence within five years post-diagnosis and 60 who had remained recurrence-free.

Enzyme-linked immunosorbent assays (ELISA’s) were used to quantify patient serum cadherin-5 (CDH5) levels and assess glycosylation by Helix pomatia agglutinin (HPA) binding. The reaction was monitored using a Dynatech MRX plate reader (Dynatech Medical Products, Alexandria, VA, USA), and following quenching the absorbance was read at 450 nm in a Wallac 1420 Victor 2 plate reader (Perkin Elmer, Beaconsfield, UK). Serum cancer antigen 15.3 (CA15.3), and carcinoembryonic antigen (CEA), and Vascular endothelial growth factor (VEGF) levels were also measured.

The investigators detected higher levels of a protein called CDH5 that had unusual sugars decorating its surface in women who went on to be diagnosed with secondary breast cancer over a year later. This indicates that the sensitivity of current blood tests could be improved upon for earlier diagnosis of secondary disease. Serum CDH5 levels and CDH5:HPA ratio values showed these biomarkers to be significantly elevated in patients with metastatic breast cancer, a finding which was paralleled by measurements of CA15.3, which is a more specific but less sensitive marker than CDH:HPA ratios.

Miriam Dwek, PhD, who leads the cancer group, said, “The blood test worked particularly well at identifying metastasis in a sub-group of patients with estrogen responsive breast cancers, which make up 70% of all breast cancers diagnosed. We are excited and hope to develop this test further so in the future there will be improved methods for the better monitoring of patients.” The study was published on March 24, 2016, in the journal British Journal of Cancer.

Related Links:
University of Westminster
Dynatech Medical Products


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.